The AUC for SHI was 0.56 (95% CI, 0.48–0.65; Sensitivity, 0.169; Specificity, 0.959; Youden's index, 0.128) for TTR, and 0.54 (95% CI, 0.44–0.663; Sensitivity, 0.157; Specificity, 0.919; Youden's index, 0.076) for OS (Supplementary Table 1), which was the strongest factor among clinical factors [tumor size, tumor number, tumor differentiation, tumor encapsulation, vascular invasion, α-fetoprotein (AFP), and Barcelona Clinic Liver Cancer (BCLC) stage] for predicting tumor recurrence and survival of HBV-HCC patients. Here, AFP is linked to hepatocellular carcinoma.